Last $10.88 USD
Change Today -0.65 / -5.64%
Volume 83.2K
CLDN On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 1:30 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

celladon corp (CLDN) Snapshot

Open
$11.72
Previous Close
$11.53
Day High
$11.83
Day Low
$10.68
52 Week High
03/17/14 - $17.16
52 Week Low
02/4/14 - $7.45
Market Cap
245.2M
Average Volume 10 Days
128.1K
EPS TTM
$-15.10
Shares Outstanding
22.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLADON CORP (CLDN)

Related News

No related news articles were found.

celladon corp (CLDN) Related Businessweek News

No Related Businessweek News Found

celladon corp (CLDN) Details

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart. Its MYDICAR product is developed to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company was founded in 2000 and is headquartered in San Diego, California.

22 Employees
Last Reported Date: 08/7/14
Founded in 2000

celladon corp (CLDN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $417.5K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $216.3K
Vice President of Corporate Development & Inv...
Total Annual Compensation: $190.4K
Vice President of Clinical Operations
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2013.

celladon corp (CLDN) Key Developments

Celladon Corporation Announces Initiation of Clinical Trial to Investigate MYDICAR in Patients with Heart Failure and a Left Ventricular Assist Device (LVAD)

Celladon Corporation announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure and a Left Ventricular Assist Device (LVAD)," which is designed to assess the potential utility of MYDICAR in advanced heart failure patients whose hearts are being supported by LVADs. This trial is partially funded by the British Heart Foundation and sponsored by Imperial College London. This proof-of-concept study is expected to evaluate 24 patients with varying levels of neutralizing antibodies to determine the safety and feasibility of using MYDICAR to treat advanced heart failure patients with LVADs, how well MYDICAR delivers the gene for SERCA2a to heart cells and the impact of circulating neutralizing antibodies to AAV1 on the ability of MYDICAR to deliver the SERCA2a gene to heart muscle cells. Of the patients enrolled in the study, 16 will be treated with MYDICAR and eight will be treated with placebo. Safety data and changes in heart function as assessed by tissue Doppler echocardiography, six-minute walk tests, cardiopulmonary exercise and metabolic stress tests will be collected and analyzed. In addition, as an exploratory sub-study, patients will be assessed to see whether their cardiac function improves enough to support being potentially weaned off their LVADs. Six months post-treatment, all patients will undergo a heart biopsy for collection of tissue to determine the presence of the SERCA2a gene. Additionally, Celladon recently completed enrollment of a 250-patient Phase 2b CUPID2 clinical trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying of, heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of high-dose MYDICAR versus placebo, added to a maximal, optimized heart failure regimen in patients with New York Heart Association (NYHA) class III or IV symptoms of chronic heart failure due to systolic dysfunction. The Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for this program and expects to report results from this clinical trial in April 2015.

Celladon Corporation Announces Consolidated Earnings Results for the Second Quarter of 2014

Celladon Corporation announced consolidated earnings results for the second quarter of 2014. For the quarter, the company reported net loss of $7.0 million against $4.9 million a year ago. Loss from operations was $7,005,000 against $4,992,000 a year ago.

Celladon Corporation Secures $25 Million Credit Facility from Hercules Technology Growth Capital, Inc

Celladon Corporation announced that it has entered into a credit facility with Hercules Technology Growth Capital Inc. and its affiliate lenders. The credit facility provides for up to $25 million of loans. The company drew a first tranche of $10 million at the closing of the new credit facility. A second tranche of up to $15 million can be drawn, at Celladon's option, prior to May 31, 2015. This option may be exercised if data from the ongoing Phase 2b trial of MYDICAR supports the continued development of MYDICAR for its Breakthrough Therapy indication to either a Phase III study or registration for approval, as reasonably determined by Celladon's senior management and board of directors. MYDICAR has received Breakthrough Therapy designation from the FDA for reducing hospitalization for heart failure in Nab-negative NYHA class III or class IV heart failure patients who are not in immediate need of a left ventricular assist device or heart transplant. The company expects to report results from the Phase 2b trial in April 2015. The company plans to use the proceeds from the credit facility to provide additional funding for the development of MYDICAR, for other development programs in its pipeline, and for general corporate purposes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLDN:US $10.88 USD -0.65

CLDN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLDN.
View Industry Companies
 

Industry Analysis

CLDN

Industry Average

Valuation CLDN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLADON CORP, please visit www.celladon.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.